Efficacy of Liraglutide Therapy in Patients With IPAA

Inclusion Criteria: * Informed consent will be obtained before any trial-related procedures * Age \> 18 years * Patients with IPAA and bowel frequency \> 8 bowel movements in 24 hours on at least 4 of 7 days/week and presence of high bowel frequency \> 4 weeks despite adequate therapy for acute pouchitis or Crohn's like disease of the pouch Exclusion Criteria: * Significant pouch inflammation defined as an endoscopic pouch disease activity index (PDAI ) ≥ 4 * Known stricture of the ileo-anal anastomosis or afferent limb stricture * New onset of high bowel frequency in the setting of acute pouchitis * IPAA since \< 6 months * Known Clostridium difficile pouchitis * Known clinically significant chronic nausea and/or vomiting in the past * Known type 1 or type 2 diabetes * History of or active neoplasia * Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 * Renal impairment defined as glomerular filtration rate (glomerular filtration rate \< 30) * Clinically significant decompensated liver disease defined as elevation of aspartate aminotransferase , alanine transaminase or bilirubin \> 2-fold the upper limits of normal (Primary Sclerosing Cholangitis with liver function tests (LFT's) \<1.5 upper limits of normal can be included) * New York Heart Association class 3 or greater heart failure or recent (within 6 months) cardiovascular event * Prior history of pancreatitis * Prior treatment with a GLP-1receptor agonist * Know…